AstraZeneca says Mylan, Kindeva infringe another Symbicort patent

AstraZeneca filed a patent infringement lawsuit against Mylan Pharmaceuticals and Kindeva Drug Delivery on Tuesday, claiming that their generic asthma Symbicort (budesonide/formoterol) infringes a brand-new patent that was issued the same day.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

Generic drug maker fails to avoid inhaler patent lawsuit

14 July 2022 A Virginia court was unconvinced that the Hatch-Waxman Act did not apply.

Big Pharma

Roche and AstraZeneca units settle blood drug suit

17 February 2022 Roche’s Chugai and AstraZeneca’s Alexion Pharmaceuticals have brought their patent infringement dispute over a treatment for rare, fatal blood diseases to an end.

Americas

AstraZeneca aims to stifle Mylan’s revived shot at generic inhaler

27 January 2022 AstraZeneca has urged the US Court of Appeals for the Federal Circuit to revisit a split panel decision that breathed new life into Mylan’s bid to produce a generic version of the asthma inhaler, Symbicort Turbohaler.

More on this story

Big Pharma

Generic drug maker fails to avoid inhaler patent lawsuit

14 July 2022 A Virginia court was unconvinced that the Hatch-Waxman Act did not apply.

Big Pharma

Roche and AstraZeneca units settle blood drug suit

17 February 2022 Roche’s Chugai and AstraZeneca’s Alexion Pharmaceuticals have brought their patent infringement dispute over a treatment for rare, fatal blood diseases to an end.

Americas

AstraZeneca aims to stifle Mylan’s revived shot at generic inhaler

More on this story

Big Pharma

Generic drug maker fails to avoid inhaler patent lawsuit

14 July 2022 A Virginia court was unconvinced that the Hatch-Waxman Act did not apply.

Big Pharma

Roche and AstraZeneca units settle blood drug suit

17 February 2022 Roche’s Chugai and AstraZeneca’s Alexion Pharmaceuticals have brought their patent infringement dispute over a treatment for rare, fatal blood diseases to an end.

Americas

AstraZeneca aims to stifle Mylan’s revived shot at generic inhaler